Targeting HIV Retention and Improved Viral Load Through Engagement ('THRIVE')

Depression Clinical Trial

Official title:

Targeting HIV Retention and Improved Viral Load Through Engagement ('THRIVE')

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04481373
• Other study ID #: H-47444
• Status: Completed
• Phase: N/A
• Start date: March 3, 2021
• Est. completion date: February 29, 2024

Study information

• Verified date: April 2024
• Source: Baylor College of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Many people with HIV infection are not consistently engaged in outpatient HIV care, and avoidance, stigma and denial contribute to poor engagement in HIV care. This project will develop and pilot test a new intervention, "THRIVE," for hospitalized persons who are out of HIV care and endorse avoidance, to improve how well they stay in outpatient HIV care after discharge. If successfully developed, the intervention will undergo large scale testing in later studies and could improve the health of persons with HIV infection and help end the HIV epidemic in the United States.

Description:

Poor retention in HIV primary care results in lower rates of HIV viral suppression, higher rates of HIV transmission, and exacerbates racial and ethnic disparities in health outcomes, including survival. To date, there are no interventions that effectively relink and retain PWH in care when they are found outside the HIV clinic. Many persons with HIV infection (PWH) are hospitalized with life-threatening but preventable complications of inadequately treated HIV infection. They are among the most important patients to retain in care. Our previous research shows that among PWH who are out of care and hospitalized, avoidance coping, stigma, and mental health difficulties were nearly universal. Further, avoidance coping was a predictor of failure to re-engage in care after discharge. Acceptance and Commitment Therapy (ACT) is a transdiagnostic intervention with the capacity to address a range of psychosocial and behavior-related issues that PWH experience. ACT helps patients overcome avoidance, particularly avoidance of uncomfortable internal states and the situations that trigger such states, by promoting acceptance-based coping and re-engagement in meaningful and valued-life activities. Brief ACT interventions appear to be feasible, acceptable, and at least preliminarily, have efficacy. The investigators propose to develop, refine, and pilot a brief (4-5 contact hours) ACT intervention for hospitalized, out-of-care PWH. 'Targeting HIV Retention and Improved Viral load through Engagement' ('THRIVE') will aim to help patients overcome avoidance, a maladaptive coping strategy implicated in a range of problems, including depression, anxiety, substance abuse, and HIV-related self-stigma, all of which constitute barriers to care. Delivering THRIVE in the hospital with a phone booster session after discharge will increase therapy initiation and completion, the lack of which is often the greatest obstacle to effective delivery of mental health services for PWH. In Aim 1, a brief hospital-based transdiagnostic, individually delivered ACT intervention (THRIVE) tailored specifically for out-of-care hospitalized PWH will be developed. Input from a multi-disciplinary team of expert care providers and PHW will be utilized to create the therapist protocol and patient workbook. The investigators will then pilot THRIVE in 10 hospitalized out-of-care PWH who will provide qualitative feedback on the intervention. The feedback, along with input from patients and the multi-disciplinary team, will be used to refine THRIVE. In Aim 2, the investigators will conduct a pilot randomized clinical trial (RCT) of the refined THRIVE intervention (N=35) compared to treatment as usual (N=35). This pilot RCT will 1) evaluate feasibility and acceptability for a full-scale RCT; and 2) examine trends in outcomes of interest for the definitive RCT. The investigators will then be positioned to submit a separate grant to test the efficacy of THRIVE in a fully powered randomized trial. This work has the potential to decrease HIV morbidity and racial/ethnic disparities and contribute to ending the HIV epidemic in the United States, which are NIH priorities.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 75
• Est. completion date: February 29, 2024
• Est. primary completion date: February 29, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Hospitalized at Ben Taub Hospital, Houston, TX;

• at least 18 years of age;

• able to speak English or Spanish;

• HIV infected;

• able to provide informed consent and participate in the study (patients who are temporarily unable to participate will be followed and approached for enrollment if and when they are cognitively and physically capable of consenting and participating);

• HIV VL>1000 c/mL;

• never in care or currently out of HIV care, defined as not meeting the 'visit constancy' measure (=1 completed HIV primary care visit at Thomas Street Health Center (TSHC), Houston, TX, in each of the three 4-month intervals preceding admission); or =2 "no shows" to HIV primary care visits at TSHC in the last year.

• endorse one of two avoidance coping statements with the highest factor loadings on the Avoidant Coping Subscale from the Coping with HIV/AIDS scale

Exclusion Criteria:

• intending to use a source of HIV primary care other than TSHC after discharge, because their outcomes cannot be evaluated;

• in the opinion of the primary medical team caring for the patient, likely to be discharged to an institutional setting, die in the hospital or enter hospice;

• incarcerated or expected to be discharged to prison or jail;

• enrolled in another research study with prospective follow-up;

• pregnant, since pregnant women receive additional efforts to be linked and retained in care;

• admitted with acute psychosis which would preclude informed consent or meaningful participation with the intervention.

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• Anxiety
• Depression
• HIV Infections
• Human Immunodeficiency Virus

Intervention

Behavioral:
• THRIVE
The ACT components (3-3.5 hours) will focus on clarifying patient values and goals and identifying obstacles that may be getting in the way of living a rich life. Short-and long-term effects of avoidance will be discussed (e.g., avoidance reduces immediate contact with distressing experiences and provides short-term relief but leads to greater dysfunction in long run). Patients will be taught acceptance, mindfulness, and perspective taking to help patient cope with difficult emotions and thoughts that may interfere with living a values-driven life. Individuals will also be encouraged to examine the costs of stigmatization on their life (e.g. avoidance of medical care, sense of isolation). Education will include medical information about HIV, services available at the clinic, and health needs related to comorbidities. This content to be delivered in 30 minutes.

Other:
• Treatment as Usual
Patients get usual care at the hospital. Service linkage workers (SLWs) meet with all hospitalized PWH and cover educational aspects of the care.

Locations

Country	Name	City	State
United States	Ben Taub Hospital	Houston	Texas

Sponsors (4)

Lead Sponsor	Collaborator
Baylor College of Medicine	Brown University, University of Iowa, University of Texas

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Internalized AIDS-Related Stigma Scale (IARSS)	This is a 6-item measure examines internalized stigma. Response scores range from 0 (low stigma)-6 (high stigma) with higher scores representing higher levels of stigma.	6 months
Other	Depression Anxiety and Stress Scale (DASS-21).	This is a 21-item measure. The total score ranges from 0-120 with higher scores reflecting higher levels of distress including depression, anxiety, and stress.	6 months
Other	Alcohol Use Disorders Identification Test (AUDIT)	This 3-item screener that identifies problem alcohol use for both men and women. Participants respond on a 5-point scale. Higher numbers represent more difficulty.	6 months
Other	The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)	This measure asks about substance use of 7 categories of drugs in the previous 3 months and in a person's life time. Participants respond YES or NO to each category of drugs.	6 months
Other	Coping with HIV/AIDS scale	This is a 16 item measure that examines positive coping, avoidant coping, and social support. Items are scores from 1-3 with higher scores reflecting greater positive coping, greater avoidant coping, and greater social support.	6 months
Other	Client Satisfaction Questionnaire (CSQ)	This 8-item measure assesses patient satisfaction with services. Scores range from 8-32 with higher scores representing greater satisfaction.	6 months
Primary	Acceptability of enrollment and randomization	The number of eligible PWH who agree and decline to participate, and reasons for declining;	6 months
Primary	Acceptability of enrollment and randomization	The number of PWH who are not eligible to participate and the reasons for lack of eligibility.	6 months
Primary	Acceptability of the intervention	Intervention completion rate	6 months
Primary	Acceptability of the intervention	Retention of participants in follow-up assessments	6 months
Primary	Acceptability of the intervention	Duration of contacts	6 months
Secondary	Viral Load Improvement	Change in Viral Load	6 months
Secondary	Number of patients who are retained in HIV Care	Number of patients who complete at least 2 visits with an HIV clinician within 6 months	6 months